AEterna has a variety of new products in its pipeline.
Macrilen, for example, is the first and only FDA-approved oral test for the diagnosis of Adult Growth Hormone Deficiency.
AEterna received European approval to market Macrillen.
Dr. Christian Strasburger: "Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the...
The 9ema is crossing the 20ema and the current price is at the YTD POC line. The MACD crossed a few days ago . I would like to see it hold $1.03 for a long swing to: $1.45 and $1.87
Based off trend lines.
AEZS recently gained compliance
Volume has been low the last few days compared to average
Earnings to be announced on March 30th
Aeterna Zentaris Inc (NASDAQ: AEZS) has exercised its option announced on February 2, and entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-19 vaccine.
The vaccine is currently in preclinical development and was invented at the Julius-Maximilians-University in Wuerzburg.
Additionally, the Company has...
AEZS: Aeterna Zentaris Inc
2021-03-15 08:05:00
Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19
Bullish Indicators
- Falling Wedge
- Wide RSI Divergence
- Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference March 9-10
AEZS .... PULLBACK ...WEDGE SISTEM RETURN AFTER PUBBLIC OFFERT..... STAY TUNED THE SAME MODEL AS CLSN ATOS......TO BE PATIENCE AND FO.LOW THE PREVISION
Bullish Flag
Pros:
Descending volume during formation
Golden cross in blue
PPS above 50MA and 200MA
RS above 0, and ascending
ATR Ascending
R/R ratio above 8
250RSI above 50
Cons:
200MA Flat
PT = 5.09$
Running a morning scan on finviz (need to figure out how to do that here) came up with Aeterna Zentaris. One of those times it feels risky to buy a 10,000 shares at $1 and then at $3 you think, I should have bought more!
Last February this would be worth 1000%. Hard to tell how the market will treat this opportunity one year later. No reasonable charting to do...
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg
- Company secures next step to continue to build-out pipeline of assets.
- University researchers developed a proprietary and orally active bacterial vaccine...
DO NOT BUY YET
Here is a good opportunity for a pull back to .50 cents for aggressive buyers to get on board
The BUYING would be when the price breaks through the line of .75
The challenging part is NASDQ is giving 180 days to Regain Compliance with Minimum Bid Price Rule until July 23 2021 - if they don't reach that it may get delisted, and that would suck...
see easy and self explanatory boxes on chart for Entry, Exit and Stop loss zones. Never chase any stock.
Not for any recommendation, Just an Idea. Like it >> Click 👍/comment, and follow.
![AEZS: [AEZS] Trade Watch - Upside Potential headed back to MA100/200?](https://s3.tradingview.com/u/ULn3RPFh_mid.png "[AEZS] Trade Watch - Upside Potential headed back to MA100/200?")
